1 VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
2 Weill Cornell Medical College, New York, New York, USA, and Doha, Qatar.
3 Hamad Medical Corporation, Doha, Qatar.
4 University of Cincinnati School of Medicine, Cincinnati, Ohio, USA.
For persons with baseline Fibrosis-4 1.46-3.25, cirrhosis incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03). Cirrhosis risk was numerically higher but statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence intervals [CI], .37-6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).